scholarly journals Schnitzler’s Syndrome: A Case Report

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Gabriel Tinoco ◽  
Rehan Kanji ◽  
Deepthi Moola
Keyword(s):  
Case Report ◽  
Treatment Options ◽  
Current Treatment ◽  
Rare Entity ◽  
Difficult Diagnosis ◽  
Schnitzler’S Syndrome

Schnitzler’s syndrome is an extremely rare entity that poses a challenge for the clinician not only due to its difficult diagnosis but also due to its management. In this article we report a new case and briefly review the current treatment options.

Atypical Cogan's syndrome: A case report and summary of current treatment options

2015 ◽  
Vol 79 (3) ◽  
pp. 428-431 ◽  
Author(s):  
Debora Jančatová ◽  
Karol Zeleník ◽  
Pavel Komínek ◽  
Petr Matoušek
Keyword(s):  
Case Report ◽  
Treatment Options ◽  
Current Treatment ◽  
Cogan’S Syndrome ◽  
Cogan's Syndrome

scholarly journals Acute Respiratory Distress due to Thymoma in a Patient Treated with TK Inhibitor: A Case Report and Review of the Current Treatment Options

2011 ◽  
Vol 4 (1) ◽  
pp. 155-161
Author(s):  
P. Zarogoulidis ◽  
D. Matthaios ◽  
A. Iordanidis ◽  
V. Zervas ◽  
A. Mitrakas ◽  
...  
Keyword(s):  
Case Report ◽  
Respiratory Distress ◽  
Treatment Options ◽  
Current Treatment

Synovial Osteochondromatosis

2002 ◽  
Vol 92 (4) ◽  
pp. 247-254 ◽  
Author(s):  
Gerard V. Yu ◽  
Roger L. Zema ◽  
Richard W.S. Johnson
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Treatment Options ◽  
Clinical Findings ◽  
Benign Disease ◽  
Unknown Etiology ◽  
Rare Entity ◽  
Predisposing Factor ◽  
Synovial Osteochondromatosis

Synovial osteochondromatosis is a benign disease of unknown etiology that involves the articular and periarticular structures. The disorder primarily affects men, and trauma is the most common predisposing factor. The authors review the literature, clinical findings, proposed etiology, classification, ancillary tests, histopathology, differential diagnosis, treatment options, and prognosis. A case report of this rare entity is also presented. (J Am Podiatr Med Assoc 92(4): 247-254, 2002)

scholarly journals Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report

2021 ◽  
pp. 65-71
Author(s):  
Tuan Vu ◽  
Brittany Harvey ◽  
Niraja Suresh ◽  
Jerrica Farias ◽  
Clifton Gooch
Keyword(s):  
Case Report ◽  
Myasthenia Gravis ◽  
Potential Role ◽  
Treatment Options ◽  
Current Treatment ◽  
Humanized Monoclonal Antibody ◽  
Child Bearing ◽  
Positive Treatment ◽  
Treatment Refractory ◽  
Anti Acetylcholine

The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG). Myasthenia gravis (MG) often affects women of child-bearing potential. However, management can be challenging during pregnancy, and current treatment options are limited due to potential teratogenicity. Data are currently lacking on the use of eculizumab in pregnant women with gMG. This case report describes a successful pregnancy in a young woman with treatment-refractory gMG treated with eculizumab before, during, and after pregnancy. Eculizumab appeared to have a favorable benefit-risk profile in this setting, with no treatment-related adverse effects noted in either the patient or the neonate. The patient remains neurologically stable on eculizumab, which she has now been receiving for 5 years. This first report of the use of eculizumab during pregnancy in a patient with treatment-refractory gMG suggests a potential role for eculizumab in this setting, although further clinical experience is necessary to support its use during pregnancy in women with MG.

Pain Management Techniques for Loin Pain Hematuria Syndrome Case Report

2020 ◽  
pp. 141-144
Author(s):  
Sarang Koushik
Keyword(s):  
Spinal Cord ◽  
Case Report ◽  
Spinal Cord Stimulation ◽  
Renal Denervation ◽  
Treatment Options ◽  
Disease Process ◽  
Current Treatment ◽  
Flank Pain ◽  
Loin Pain ◽  
Loin Pain Hematuria Syndrome

Background: Loin pain hematuria syndrome (LPHS) is a rare syndrome presenting with chronic unilateral or bilateral flank pain and gross or microscopic hematuria. Case Report: We present a case of LPHS in a male with past medical history of atrial fibrillation, Barrett’s esophagus, and loin pain hematuria syndrome who initially presented to our medical facility with gross hematuria, intractable left flank pain, and non-bloody emesis. Our case exemplifies the challenge in managing patients with LPHS. Conclusion: Without a definitive mechanism for LPHS, current treatment focuses on symptom management. Analgesics (non-opioid and opioid) may be used orally or intravenous depending on the presence of concomitant nausea and vomiting. For patients at risk of opioid dependence, targeting afferent pain fibers originating from the kidneys and ureters has proven a successful analgesic strategy. Surgical options for renal denervation include: endovascular radiofrequency ablation, laparoscopic renal denervation, and renal auto transplant. Treatment options for this disease process include intra-ureteric bupivacaine, renal denervation, and possible spinal cord stimulation. Key words: Flank pain, loin pain hematuria syndrome, renal denervation, spinal cord stimulation

scholarly journals Impact of SARS-CoV-2 Genetic Blueprints on the Oral Manifestation of COVID-19: A Case Report

2021 ◽  
Author(s):  
Amir Khodavirdipour ◽  
Mahsa Asadimanesh ◽  
Seyed Alireza Masoumi
Keyword(s):  
Case Report ◽  
Treatment Options ◽  
Signs And Symptoms ◽  
Current Treatment ◽  
Oral Diseases ◽  
Angiotensin Converting Enzyme 2 ◽  
Oral Manifestation ◽  
Life Threatening ◽  
History Of ◽  
The Common

AbstractNonsegmented positive-sense RNA enveloped RNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can result in coronavirus disease 2019 (COVID-19). This virus is from β-coronaviridae family of viruses. The common signs and symptoms of COVID-19 include pyrexia, cough, dyspnea, fatigue, myalgia, cephalgia, diarrhea, and nausea. Physicians and dentists around the world could directly link the COVID-19 and oral diseases such as ageusia and anosmia. After time passes, different aspects of symptoms of the diseases have been discovered. Research suggests that the oral cavity is the most vulnerable region for the virus because of angiotensin-converting enzyme-2 (ACE2) receptor abundance in the mouth. In this case report (no. of patients = 6), we would like to report significant findings in patients who were diagnosed with COVID-19 reported to our clinic during May 2021 complaining about the oral manifestation of it such as xerostomia, gingival inflammation, and cracked teeth. All patients are younger than 40 years with no history of dental complaints and oral diseases. Fortunately, these symptoms are not life threatening and treatable/manageable by current treatment options. To date, there is no clear proof of how and via which pathway, SARS-CoV-2 genomic blueprint causes the oral manifestation of COVID-19 beside ACE2 receptor which is the only known biopathway for such incidents.

Sign in / Sign up

Export Citation Format

Share Document